A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors

Clinical trial NCT03420742 · COMPLETED

Trial details

NCT number

NCT03420742

Sponsor

Takeda

Status

COMPLETED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2019-06-26

Primary completion

2020-03-24

Enrollment

24

View on ClinicalTrials.gov